BioSpace News Archive

Nuvalent, Inc. announced the closing of its previously announced upsized underwritten public offering of 7,895,522 shares of Class A common stock, which includes 1,029,850 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $33.50 per share.

Akeso, Biopharma announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer who have failed to epidermal growth factor receptor tyrosine kinase inhibitor treatment.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in marketable securities on September 30, 2022 , were

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.

Myomo, Inc. today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.

Alphatec Holdings, Inc., a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced financial results for the quarter ended September 30, 2022, and recent corporate highlights.

Privia Health announced a joint venture and strategic partnership with Novant Health Enterprises, a division of Novant Health, a nationally recognized not-for-profit health system, to launch Privia Medical Group – North Carolina to bring support and resources to independent providers throughout the state.

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2022 financial results after market close on Thursday, November 10, 2022.

Vallon Pharmaceuticals, Inc. today reported its financial results for the quarter ended September 30, 2022.

Alpine Immune Sciences, Inc. today presented a poster at the American Society of Nephrology Kidney Week 2022 Meeting highlighting updated clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of ALPN-303, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.